CD47 and neoplasm: Once again, tumor immunology has led the way, with anti-CD47 Abs already in clinical trials, and showing clinical promise by way of dampening a “don't eat me” signal that otherwise spares tumor cells from destruction by monocytes and macrophages (65, 66).